Increased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients

Muhammd Toor, Azharuddin Sajid Syed Khaja, Haytham El Salhat, Omar Bekdache, Jihad Kanbar, Mohammed Jaloudi, Eyad Elkord

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Increased levels of myeloid cells, especially myeloid-derived suppressor cells (MDSCs), have been reported to correlate with bad prognosis and reduced survival in cancer patients. However, limited data are available on their conclusive phenotypes and their correlation with clinical settings. The aim of this study was to investigate levels and phenotype of myeloid cells in peripheral blood and tumor microenvironment (TME) of colorectal cancer (CRC) patients, compared to blood from healthy donors (HDs) and paired, adjacent non-tumor colon tissue. Flow cytometric analysis was performed to examine the expression of different myeloid markers in fresh peripheral blood samples from CRC patients and HDs, and tissue-infiltrating immune cells from CRC patients. We found significantly higher levels of cells expressing myeloid markers and lacking the expression of major histocompatibility complex class II molecule HLA-DR in blood and tumor of CRC patients. Further analysis revealed that these cells were granulocytic and expressed Arginase 1 indicative of their suppressive phenotype. These expanded cells could be neutrophils or granulocytic MDSCs, and we refer to them as granulocytic myeloid cells (GMCs) due to the phenotypical and functional overlap between these cell subsets. Interestingly, the expansion of peripheral GMCs correlated with higher stage and histological grade of cancer, thereby suggesting their role in cancer progression. Furthermore, an increase in CD33+CD11b+HLA-DR-CD14-CD15- immature myeloid cells was also observed in CRC tumor tissue. Our work shows that GMCs are expanded in circulation and TME of CRC patients, which provides further insights for developing immunotherapeutic approaches targeting these cell subsets to enhance antitumor immune and clinical responses.

Original languageEnglish
Article number560
JournalFrontiers in Immunology
Volume7
Issue numberDEC
DOIs
Publication statusPublished - 2016

Fingerprint

Myeloid Cells
Colorectal Neoplasms
Neoplasms
Tumor Microenvironment
HLA-DR Antigens
Phenotype
Arginase
Major Histocompatibility Complex
Blood Donors
Colon
Neutrophils
Tissue Donors
Survival

Keywords

  • Circulation
  • Colorectal cancer
  • Myeloid cells
  • Neutrophils
  • Tumor microenvironment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Increased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients. / Toor, Muhammd; Khaja, Azharuddin Sajid Syed; El Salhat, Haytham; Bekdache, Omar; Kanbar, Jihad; Jaloudi, Mohammed; Elkord, Eyad.

In: Frontiers in Immunology, Vol. 7, No. DEC, 560, 2016.

Research output: Contribution to journalArticle

Toor, Muhammd ; Khaja, Azharuddin Sajid Syed ; El Salhat, Haytham ; Bekdache, Omar ; Kanbar, Jihad ; Jaloudi, Mohammed ; Elkord, Eyad. / Increased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients. In: Frontiers in Immunology. 2016 ; Vol. 7, No. DEC.
@article{90bf2386f5d945c393ec84a5f6343871,
title = "Increased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients",
abstract = "Increased levels of myeloid cells, especially myeloid-derived suppressor cells (MDSCs), have been reported to correlate with bad prognosis and reduced survival in cancer patients. However, limited data are available on their conclusive phenotypes and their correlation with clinical settings. The aim of this study was to investigate levels and phenotype of myeloid cells in peripheral blood and tumor microenvironment (TME) of colorectal cancer (CRC) patients, compared to blood from healthy donors (HDs) and paired, adjacent non-tumor colon tissue. Flow cytometric analysis was performed to examine the expression of different myeloid markers in fresh peripheral blood samples from CRC patients and HDs, and tissue-infiltrating immune cells from CRC patients. We found significantly higher levels of cells expressing myeloid markers and lacking the expression of major histocompatibility complex class II molecule HLA-DR in blood and tumor of CRC patients. Further analysis revealed that these cells were granulocytic and expressed Arginase 1 indicative of their suppressive phenotype. These expanded cells could be neutrophils or granulocytic MDSCs, and we refer to them as granulocytic myeloid cells (GMCs) due to the phenotypical and functional overlap between these cell subsets. Interestingly, the expansion of peripheral GMCs correlated with higher stage and histological grade of cancer, thereby suggesting their role in cancer progression. Furthermore, an increase in CD33+CD11b+HLA-DR-CD14-CD15- immature myeloid cells was also observed in CRC tumor tissue. Our work shows that GMCs are expanded in circulation and TME of CRC patients, which provides further insights for developing immunotherapeutic approaches targeting these cell subsets to enhance antitumor immune and clinical responses.",
keywords = "Circulation, Colorectal cancer, Myeloid cells, Neutrophils, Tumor microenvironment",
author = "Muhammd Toor and Khaja, {Azharuddin Sajid Syed} and {El Salhat}, Haytham and Omar Bekdache and Jihad Kanbar and Mohammed Jaloudi and Eyad Elkord",
year = "2016",
doi = "10.3389/fimmu.2016.00560",
language = "English",
volume = "7",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "DEC",

}

TY - JOUR

T1 - Increased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients

AU - Toor, Muhammd

AU - Khaja, Azharuddin Sajid Syed

AU - El Salhat, Haytham

AU - Bekdache, Omar

AU - Kanbar, Jihad

AU - Jaloudi, Mohammed

AU - Elkord, Eyad

PY - 2016

Y1 - 2016

N2 - Increased levels of myeloid cells, especially myeloid-derived suppressor cells (MDSCs), have been reported to correlate with bad prognosis and reduced survival in cancer patients. However, limited data are available on their conclusive phenotypes and their correlation with clinical settings. The aim of this study was to investigate levels and phenotype of myeloid cells in peripheral blood and tumor microenvironment (TME) of colorectal cancer (CRC) patients, compared to blood from healthy donors (HDs) and paired, adjacent non-tumor colon tissue. Flow cytometric analysis was performed to examine the expression of different myeloid markers in fresh peripheral blood samples from CRC patients and HDs, and tissue-infiltrating immune cells from CRC patients. We found significantly higher levels of cells expressing myeloid markers and lacking the expression of major histocompatibility complex class II molecule HLA-DR in blood and tumor of CRC patients. Further analysis revealed that these cells were granulocytic and expressed Arginase 1 indicative of their suppressive phenotype. These expanded cells could be neutrophils or granulocytic MDSCs, and we refer to them as granulocytic myeloid cells (GMCs) due to the phenotypical and functional overlap between these cell subsets. Interestingly, the expansion of peripheral GMCs correlated with higher stage and histological grade of cancer, thereby suggesting their role in cancer progression. Furthermore, an increase in CD33+CD11b+HLA-DR-CD14-CD15- immature myeloid cells was also observed in CRC tumor tissue. Our work shows that GMCs are expanded in circulation and TME of CRC patients, which provides further insights for developing immunotherapeutic approaches targeting these cell subsets to enhance antitumor immune and clinical responses.

AB - Increased levels of myeloid cells, especially myeloid-derived suppressor cells (MDSCs), have been reported to correlate with bad prognosis and reduced survival in cancer patients. However, limited data are available on their conclusive phenotypes and their correlation with clinical settings. The aim of this study was to investigate levels and phenotype of myeloid cells in peripheral blood and tumor microenvironment (TME) of colorectal cancer (CRC) patients, compared to blood from healthy donors (HDs) and paired, adjacent non-tumor colon tissue. Flow cytometric analysis was performed to examine the expression of different myeloid markers in fresh peripheral blood samples from CRC patients and HDs, and tissue-infiltrating immune cells from CRC patients. We found significantly higher levels of cells expressing myeloid markers and lacking the expression of major histocompatibility complex class II molecule HLA-DR in blood and tumor of CRC patients. Further analysis revealed that these cells were granulocytic and expressed Arginase 1 indicative of their suppressive phenotype. These expanded cells could be neutrophils or granulocytic MDSCs, and we refer to them as granulocytic myeloid cells (GMCs) due to the phenotypical and functional overlap between these cell subsets. Interestingly, the expansion of peripheral GMCs correlated with higher stage and histological grade of cancer, thereby suggesting their role in cancer progression. Furthermore, an increase in CD33+CD11b+HLA-DR-CD14-CD15- immature myeloid cells was also observed in CRC tumor tissue. Our work shows that GMCs are expanded in circulation and TME of CRC patients, which provides further insights for developing immunotherapeutic approaches targeting these cell subsets to enhance antitumor immune and clinical responses.

KW - Circulation

KW - Colorectal cancer

KW - Myeloid cells

KW - Neutrophils

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85009360798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009360798&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2016.00560

DO - 10.3389/fimmu.2016.00560

M3 - Article

VL - 7

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - DEC

M1 - 560

ER -